A Creighton University researcher has received a National Institutes of Health grant to study the effects of gene and stem cell therapy in coronary artery bypass grafts, a first-of-its-kind undertaking that could transform the procedure, increase survival rates and dramatically reduce the possibility of re-occlusion of the grafted arteries and veins in the procedure.
Devendra K. Agrawal, Ph.D., earned the four-year, $2.9 million NIH grant after more than a decade of research and collaboration with cardiothoracic surgeons intent on improving and lengthening the success rate of coronary artery bypass grafts involving the saphenous vein in the leg. The vein is one of two most often used in coronary grafts, but studies have shown it is susceptible to new blockages, sometimes within as little as two months following a procedure.
Already at work on the strategy, Agrawal said his team is seeing a marked improvement in preventing re-occlusion, with no side effects. With continued success of the procedure in pigs, Agrawal said he’s hopeful to see a Phase 1 clinical trial for humans in the near future.
“It’s a novel and innovative approach that a number of people in my lab have worked extremely hard to make happen,” he said. “To our knowledge, nobody has done both gene therapy and stem cell therapy, but we’ve seen that you have to have both for the success of the coronary procedure and to take care of the potential for re-occlusion and thrombosis afterwards.”
Full article click here.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.